JP2020515234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515234A5 JP2020515234A5 JP2019536901A JP2019536901A JP2020515234A5 JP 2020515234 A5 JP2020515234 A5 JP 2020515234A5 JP 2019536901 A JP2019536901 A JP 2019536901A JP 2019536901 A JP2019536901 A JP 2019536901A JP 2020515234 A5 JP2020515234 A5 JP 2020515234A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- sequence
- sequence identity
- pbmc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091070501 miRNA Proteins 0.000 claims description 14
- 239000002679 microRNA Substances 0.000 claims description 9
- 108700011259 MicroRNAs Proteins 0.000 claims description 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 21
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 17
- 230000002068 genetic effect Effects 0.000 claims 13
- 229940033330 HIV vaccine Drugs 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 5
- 230000004936 stimulating effect Effects 0.000 claims 5
- 238000012258 culturing Methods 0.000 claims 4
- 230000002463 transducing effect Effects 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 210000000265 leukocyte Anatomy 0.000 claims 3
- 108091032955 Bacterial small RNA Proteins 0.000 claims 2
- 108700011778 CCR5 Proteins 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 2
- 238000003491 array Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 241000406668 Loxodonta cyclotis Species 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 5
- 239000012467 final product Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091047758 miR-185 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022189475A JP2023015407A (ja) | 2017-01-09 | 2022-11-28 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
| JP2025051839A JP2025098175A (ja) | 2017-01-09 | 2025-03-26 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444147P | 2017-01-09 | 2017-01-09 | |
| US62/444,147 | 2017-01-09 | ||
| PCT/US2018/012998 WO2018129540A1 (en) | 2017-01-09 | 2018-01-09 | Hiv immunotherapy with no pre-immunization step |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189475A Division JP2023015407A (ja) | 2017-01-09 | 2022-11-28 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515234A JP2020515234A (ja) | 2020-05-28 |
| JP2020515234A5 true JP2020515234A5 (enExample) | 2021-10-07 |
| JP7260170B2 JP7260170B2 (ja) | 2023-04-18 |
Family
ID=62790837
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536901A Active JP7260170B2 (ja) | 2017-01-09 | 2018-01-09 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
| JP2022189475A Withdrawn JP2023015407A (ja) | 2017-01-09 | 2022-11-28 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
| JP2025051839A Pending JP2025098175A (ja) | 2017-01-09 | 2025-03-26 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022189475A Withdrawn JP2023015407A (ja) | 2017-01-09 | 2022-11-28 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
| JP2025051839A Pending JP2025098175A (ja) | 2017-01-09 | 2025-03-26 | 事前の免疫化ステップのないｈｉｖ免疫療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200384021A1 (enExample) |
| EP (1) | EP3565564A4 (enExample) |
| JP (3) | JP7260170B2 (enExample) |
| KR (3) | KR20240023703A (enExample) |
| CN (2) | CN118931843A (enExample) |
| AU (2) | AU2018205388A1 (enExample) |
| BR (1) | BR112019014082A2 (enExample) |
| CA (1) | CA3048643A1 (enExample) |
| IL (1) | IL267794A (enExample) |
| WO (1) | WO2018129540A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| JP6890831B2 (ja) | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| AU2017207906B2 (en) | 2016-01-15 | 2021-03-11 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| WO2018009246A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| JP2021519069A (ja) * | 2018-03-27 | 2021-08-10 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 遺伝子改変リンパ球の製造方法 |
| KR20220150320A (ko) * | 2020-03-03 | 2022-11-10 | 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 | Hiv 치료를 위한 림프구에서 외생성 인자의 주문형 발현 |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| JP2024110682A (ja) | 2023-02-03 | 2024-08-16 | 帝人株式会社 | ポリオレフィン微多孔膜 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU725143B2 (en) * | 1996-10-17 | 2000-10-05 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| KR20040054699A (ko) * | 2001-10-02 | 2004-06-25 | 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 | 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물 |
| EP1590002A4 (en) * | 2003-01-17 | 2007-02-28 | Univ Florida | siRNA GENE THERAPY |
| US20070275010A1 (en) * | 2003-09-18 | 2007-11-29 | Mark Feinberg | Mva Vaccines |
| CN101160055A (zh) * | 2005-02-16 | 2008-04-09 | 莱蒂恩公司 | 慢病毒载体及其用途 |
| WO2010051521A1 (en) * | 2008-10-31 | 2010-05-06 | Lentigen Corporation | Cell therapy product for the treatment of hiv infection |
| EP2191834A1 (en) * | 2008-11-26 | 2010-06-02 | Centre National De La Recherche Scientifique (Cnrs) | Compositions and methods for treating retrovirus infections |
| US8728458B2 (en) * | 2009-04-30 | 2014-05-20 | The Regents Of The University Of California | Combination anti-HIV vectors, targeting vectors, and methods of use |
| JP5828838B2 (ja) * | 2009-07-15 | 2015-12-09 | カリミューン， インコーポレーティッド | ヒト免疫不全ウイルス阻害のための二重ベクター |
| WO2011103417A2 (en) * | 2010-02-18 | 2011-08-25 | Emory University Of Technology Transfer | Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response |
| CN107405357B (zh) * | 2014-10-14 | 2021-12-31 | 德克萨斯科技大学系统 | 多重shRNAs及其应用 |
| JP6890831B2 (ja) * | 2015-07-08 | 2021-06-18 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖ予備免疫化および免疫療法 |
| WO2017139065A1 (en) * | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2018009246A1 (en) * | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
-
2018
- 2018-01-09 BR BR112019014082-4A patent/BR112019014082A2/pt not_active Application Discontinuation
- 2018-01-09 KR KR1020247004866A patent/KR20240023703A/ko active Pending
- 2018-01-09 KR KR1020237020872A patent/KR20230093381A/ko not_active Ceased
- 2018-01-09 US US16/476,529 patent/US20200384021A1/en active Pending
- 2018-01-09 JP JP2019536901A patent/JP7260170B2/ja active Active
- 2018-01-09 CN CN202410957212.2A patent/CN118931843A/zh active Pending
- 2018-01-09 CN CN201880016715.2A patent/CN110462029B/zh active Active
- 2018-01-09 EP EP18736295.9A patent/EP3565564A4/en active Pending
- 2018-01-09 CA CA3048643A patent/CA3048643A1/en active Pending
- 2018-01-09 KR KR1020197023287A patent/KR102663972B1/ko active Active
- 2018-01-09 AU AU2018205388A patent/AU2018205388A1/en not_active Abandoned
- 2018-01-09 WO PCT/US2018/012998 patent/WO2018129540A1/en not_active Ceased
-
2019
- 2019-07-02 IL IL267794A patent/IL267794A/en unknown
-
2022
- 2022-11-28 JP JP2022189475A patent/JP2023015407A/ja not_active Withdrawn
-
2024
- 2024-03-01 AU AU2024201392A patent/AU2024201392A1/en active Pending
-
2025
- 2025-03-26 JP JP2025051839A patent/JP2025098175A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515234A5 (enExample) | ||
| US20240252615A1 (en) | Pre-immunization and immunotherapy | |
| Narasipura et al. | Role of β-catenin and TCF/LEF family members in transcriptional activity of HIV in astrocytes | |
| Perron et al. | Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis | |
| US11911458B2 (en) | HIV pre-immunization and immunotherapy | |
| JP2019525914A5 (enExample) | ||
| Zhou et al. | SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans | |
| JP2022166288A5 (enExample) | ||
| JP2022101658A5 (enExample) | ||
| BR112019014082A2 (pt) | Imunoterapia para hiv sem etapa de pré-imunização | |
| Breed et al. | Elite control, gut CD4 T cell sparing, and enhanced mucosal T cell responses in Macaca nemestrina infected by a simian immunodeficiency virus lacking a gp41 trafficking motif | |
| Zheng et al. | Fish TRIM21 exhibits antiviral activity against grouper iridovirus and nodavirus infection | |
| WO2019191314A1 (en) | Methods of manufacturing genetically-modified lymphocytes | |
| Wang et al. | Characterization of equine infectious anemia virus long terminal repeat quasispecies in vitro and in vivo | |
| Maury | Regulation of equine infectious anemia virus expression | |
| Li et al. | Effect of HIV-1 Tat on Secretion of TNF-α and IL-1β by U87 Cells in AIDS Patients with or without AIDS Dementia Complex | |
| Berry et al. | Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8) | |
| Dash et al. | Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection | |
| Calonge et al. | Different expression of interferon-stimulated genes in response to HIV-1 infection in dendritic cells based on their maturation state | |
| Domingues et al. | Novel approaches for HTLV-1 therapy: innovative applications of CRISPR-Cas9 | |
| Nüesch et al. | Proteins specifically binding to the 3′ untranslated region of hepatitis A virus RNA in persistently infected cells | |
| Johnson et al. | Identification of European bat lyssavirus isolates with short genomic insertions | |
| Kusagawa et al. | Isolation and characterization of a full-length molecular DNA clone of Ghanaian HIV type 1 intersubtype A/G recombinant CRF02_AG, which is replication competent in a restricted host range | |
| ZA200300996B (en) | Process for the selection of Hiv-1 subtype C isolates, selected Hiv-1 subtype isolates, their genes and modification and derivatives thereof. | |
| Jalilian et al. | An in-vitro transcription assay for development of Rotavirus VP7 |